Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SC-43 是一种具有口服活性的SHP-1 (PTPN6)激动剂。它是Sorafenib 的衍生物,可抑制STAT3的磷酸化并诱导细胞凋亡,具有抗纤维化和抗癌作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 763 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 2,890 | 现货 | ||
25 mg | ¥ 4,780 | 现货 | ||
50 mg | ¥ 6,830 | 现货 | ||
100 mg | ¥ 9,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,260 | 现货 |
产品描述 | SC-43 is a potent and orally active agonist of SHP-1 (PTPN6). SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis, and with anti-fibrotic and anticancer effects. |
体外活性 | SC-43, a sorafenib derivative.SC-43-induced apoptosis in cholangiocarcinoma (CCA) via a novel mechanism.?Three CCA cell lines (HuCCT-1, KKU-100 and CGCCA) were treated with SC-43 to determine their sensitivity to SC-43-induced cell death and apoptosis.?SC-43 activated SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation, which induced G2-M arrest and apoptotic cell death.?Importantly, SC-43 augmented SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition.?Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 counteracted the effect of SC-43-induced SHP-1 phosphatase activation and antiproliferation ability in CCA cells[1]. |
体内活性 | In vivo assay revealed that SC-43 exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation[1]. |
分子量 | 431.8 |
分子式 | C21H13ClF3N3O2 |
CAS No. | 1400989-25-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (231.59 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3159 mL | 11.5794 mL | 23.1589 mL | 57.8972 mL |
5 mM | 0.4632 mL | 2.3159 mL | 4.6318 mL | 11.5794 mL | |
10 mM | 0.2316 mL | 1.1579 mL | 2.3159 mL | 5.7897 mL | |
20 mM | 0.1158 mL | 0.579 mL | 1.1579 mL | 2.8949 mL | |
50 mM | 0.0463 mL | 0.2316 mL | 0.4632 mL | 1.1579 mL | |
100 mM | 0.0232 mL | 0.1158 mL | 0.2316 mL | 0.579 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SC-43 1400989-25-4 Apoptosis JAK/STAT signaling Metabolism Stem Cells Phosphatase STAT antiproliferative Inhibitor SHP-1 PTPN6 SC43 caspase-3 anti-fibrotic p-STAT3 anticancer orally PARP SC 43 inhibit inhibitor